Summary of Study ST001188

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000800. The data can be accessed directly via it's Project DOI: 10.21228/M88M3Q This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001188
Study TitleP. falciparum infected erythrocytes
Study SummaryMetabolite profiling across the 1st and 2nd intraerythrocytic developmental lifecycles of the malaria parasite P. falciparum following induction of delayed death with indolmycin treatment
Institute
University of Melbourne
Last NameCobbold
First NameSimon
AddressBio21 Institute, 30 Flemington Road
Emailsimon.cobbold@unimelb.edu.au
Phone383442351
Submit Date2018-10-18
Raw Data AvailableYes
Raw Data File Type(s)d
Analysis Type DetailLC-MS
Release Date2019-07-17
Release Version1
Simon Cobbold Simon Cobbold
https://dx.doi.org/10.21228/M88M3Q
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000800
Project DOI:doi: 10.21228/M88M3Q
Project Title:Delayed death in P. falciparum
Project Summary:Metabolite profiling across the 1st and 2nd intraerythrocytic developmental lifecycles of the malaria parasite P. falciparum following induction of delayed death with indolmycin treatment
Institute:University of Melbourne
Last Name:Cobbold
First Name:Simon
Address:Bio21 Institute
Email:simon.cobbold@unimelb.edu.au
Phone:383442351

Subject:

Subject ID:SU001255
Subject Type:Cultured cells
Subject Species:Plasmodium falciparum
Taxonomy ID:5833

Factors:

Subject type: Cultured cells; Subject species: Plasmodium falciparum (Factor headings shown in green)

mb_sample_id local_sample_id Treatment Time (hr)
SA08249230h_Control_n=2_2Control 30
SA08249330h_Control_n=2_3Control 30
SA08249430h_Control_n=1_3Control 30
SA08249530h_Control_n=2_1Control 30
SA08249630h_Control_n=1_2Control 30
SA08249730h_Control_n=3_1Control 30
SA08249830h_Control_n=1_1Control 30
SA08249930h_Control_n=3_2Control 30
SA08250058h_Control_n=2_3Control 58
SA08250158h_Control_n=2_1Control 58
SA08250258h_Control_n=3_1Control 58
SA08250358h_Control_n=3_2Control 58
SA08250458h_Control_n=2_2Control 58
SA08250558h_Control_n=1_2Control 58
SA08250658h_Control_n=3_3Control 58
SA08250758h_Control_n=1_1Control 58
SA08250858h_Control_n=1_3Control 58
SA08250968h_Control_n=3_3Control 68
SA08251068h_Control_n=3_2Control 68
SA08251168h_Control_n=2_3Control 68
SA08251268h_Control_n=3_1Control 68
SA08251368h_Control_n=2_2Control 68
SA08251468h_Control_n=2_1Control 68
SA08251568h_Control_n=1_1Control 68
SA08251668h_Control_n=1_3Control 68
SA08251778h_Control_n=2_2Control 78
SA08251878h_Control_n=2_1Control 78
SA08251978h_Control_n=2_3Control 78
SA08252078h_Control_n=1_3Control 78
SA08252178h_Control_n=1_2Control 78
SA08252278h_Control_n=3_2Control 78
SA08252378h_Control_n=3_3Control 78
SA08252478h_Control_n=3_1Control 78
SA08252578h_Control_n=1_1Control 78
SA08252688h_Control_n=3_2Control 88
SA08252788h_Control_n=3_3Control 88
SA08252888h_Control_n=2_3Control 88
SA08252988h_Control_n=1_1Control 88
SA08253088h_Control_n=3_1Control 88
SA08253188h_Control_n=1_2Control 88
SA08253288h_Control_n=2_2Control 88
SA08253388h_Control_n=2_1Control 88
SA08253488h_Control_n=1_3Control 88
SA08253530h_Indolmycin_n=3_2Indolmycin 30
SA08253630h_Indolmycin_n=3_1Indolmycin 30
SA08253730h_Indolmycin_n=2_3Indolmycin 30
SA08253830h_Indolmycin_n=2_2Indolmycin 30
SA08253930h_Indolmycin_n=2_1Indolmycin 30
SA08254030h_Indolmycin_n=1_2Indolmycin 30
SA08254130h_Indolmycin_n=1_3Indolmycin 30
SA08254230h_Indolmycin_n=1_1Indolmycin 30
SA08254358h_Indolmycin_n=3_1Indolmycin 58
SA08254458h_Indolmycin_n=1_3Indolmycin 58
SA08254558h_Indolmycin_n=1_2Indolmycin 58
SA08254658h_Indolmycin_n=1_1Indolmycin 58
SA08254758h_Indolmycin_n=3_3Indolmycin 58
SA08254858h_Indolmycin_n=2_3Indolmycin 58
SA08254958h_Indolmycin_n=2_1Indolmycin 58
SA08255058h_Indolmycin_n=2_2Indolmycin 58
SA08255158h_Indolmycin_n=3_2Indolmycin 58
SA08255268h_Indolmycin_n=3_1Indolmycin 68
SA08255368h_Indolmycin_n=3_3Indolmycin 68
SA08255468h_Indolmycin_n=3_2Indolmycin 68
SA08255568h_Indolmycin_n=2_3Indolmycin 68
SA08255668h_Indolmycin_n=2_2Indolmycin 68
SA08255768h_Indolmycin_n=2_1Indolmycin 68
SA08255868h_Indolmycin_n=1_3Indolmycin 68
SA08255968h_Indolmycin_n=1_2Indolmycin 68
SA08256068h_Indolmycin_n=1_1Indolmycin 68
SA08256178h_Indolmycin_n=3_3Indolmycin 78
SA08256278h_Indolmycin_n=1_3Indolmycin 78
SA08256378h_Indolmycin_n=1_1Indolmycin 78
SA08256478h_Indolmycin_n=3_1Indolmycin 78
SA08256578h_Indolmycin_n=1_2Indolmycin 78
SA08256678h_Indolmycin_n=3_2Indolmycin 78
SA08256778h_Indolmycin_n=2_1Indolmycin 78
SA08256878h_Indolmycin_n=2_2Indolmycin 78
SA08256978h_Indolmycin_n=2_3Indolmycin 78
SA08257088h_Indolmycin_n=2_1Indolmycin 88
SA08257188h_Indolmycin_n=2_2Indolmycin 88
SA08257288h_Indolmycin_n=3_3Indolmycin 88
SA08257388h_Indolmycin_n=3_1Indolmycin 88
SA08257488h_Indolmycin_n=1_2Indolmycin 88
SA08257588h_Indolmycin_n=1_1Indolmycin 88
SA08257688h_Indolmycin_n=1_3Indolmycin 88
SA08257788h_Indolmycin_n=2_3Indolmycin 88
SA08257888h_Indolmycin_n=3_2Indolmycin 88
Showing results 1 to 87 of 87

Collection:

Collection ID:CO001249
Collection Summary:1x108 Cells per technical replicate were aliquoted into an individual microcentrifuge tube, centrifuged, washed once with 1mL ice-cold PBS, centrifuged, and metabolites extracted with 150uL 80% acetonitrile
Sample Type:Cultured cells

Treatment:

Treatment ID:TR001270
Treatment Summary:Prior to metabolite extraction, P. falciparum-infected human erythrocyte cultures were treated/untreated with indolmycin

Sample Preparation:

Sampleprep ID:SP001263
Sampleprep Summary:Following metabolite extraction with 80% acetontrile. Samples were centrifuged at top speed for 5 minutes and the supernatant collected. Metabolite samples were then stored at -80 until ready for LC-MS analysis

Combined analysis:

Analysis ID AN001980
Analysis type MS
Chromatography type HILIC
Chromatography system Agilent 6550
Column SeQuant ZIC-HILIC (150 x 4.6mm,3.5um)
MS Type ESI
MS instrument type QTOF
MS instrument name Agilent 6550 QTOF
Ion Mode NEGATIVE
Units ion count

Chromatography:

Chromatography ID:CH001429
Methods Filename:pHILIC 45 minute
Instrument Name:Agilent 6550
Column Name:SeQuant ZIC-HILIC (150 x 4.6mm,3.5um)
Column Pressure:50-150 bar
Column Temperature:35
Flow Gradient:80%
Flow Rate:0.3 mL/minute
Injection Temperature:4
Solvent A:100% water; 20 mM ammonium formate
Solvent B:100% acetonitrile
Chromatography Type:HILIC

MS:

MS ID:MS001834
Analysis ID:AN001980
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
MS Comments:Full m/z scan range across 2-35 minutes. Extended dynamic range, 0-1700 m/z
Ion Mode:NEGATIVE
  logo